Free Trial

Codexis' (CDXS) "Overweight" Rating Reiterated at Stephens

Codexis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Stephens reiterated its Overweight rating on Codexis and kept a $5 price target, implying 331% upside from the prior closing price.
  • Analyst sentiment is mixed: MarketBeat’s consensus rating is Hold, with an average price target of $6. Codexis most recently reported a quarterly loss of $0.08 per share, better than estimates, and revenue of $19.26 million, also above expectations.
  • Shares opened at $1.16 and ranged from $0.90 to $2.98 over the past year; institutional investors and hedge funds owned 78.54% of the stock.
  • Five stocks we like better than Codexis.

Codexis (NASDAQ:CDXS - Get Free Report)'s stock had its "overweight" rating reiterated by research analysts at Stephens in a note issued to investors on Monday, Benzinga reports. They presently have a $5.00 target price on the biotechnology company's stock. Stephens's target price indicates a potential upside of 331.03% from the company's previous close.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings raised shares of Codexis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 23rd. Benchmark reissued a "hold" rating on shares of Codexis in a report on Thursday, August 20th. Piper Sandler decreased their price objective on shares of Codexis from $9.00 to $8.00 and set an "overweight" rating on the stock in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Codexis from a "sell" rating to a "hold" rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $6.00.

View Our Latest Analysis on CDXS

Codexis Stock Performance

Shares of CDXS stock opened at $1.16 on Monday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 2.99 and a current ratio of 3.06. Codexis has a fifty-two week low of $0.90 and a fifty-two week high of $2.98. The stock has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $1.78. The company has a market capitalization of $127.03 million, a P/E ratio of -5.80 and a beta of 2.38.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. Codexis had a negative net margin of 21.77% and a negative return on equity of 45.54%. The firm had revenue of $19.26 million for the quarter, compared to analysts' expectations of $18.72 million. Analysts expect that Codexis will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On Codexis

Several hedge funds have recently made changes to their positions in CDXS. BlackRock Inc. purchased a new stake in shares of Codexis in the 2nd quarter worth about $16,463,000. Nantahala Capital Management LLC bought a new stake in shares of Codexis during the 2nd quarter valued at about $8,189,365. Man Group plc bought a new stake in shares of Codexis during the 2nd quarter valued at about $1,278,000. Assenagon Asset Management S.A. increased its position in shares of Codexis by 70.2% during the second quarter. Assenagon Asset Management S.A. now owns 1,278,206 shares of the biotechnology company's stock valued at $2,889,000 after buying an additional 527,036 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of Codexis during the second quarter valued at about $247,836. 78.54% of the stock is owned by hedge funds and other institutional investors.

About Codexis

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Further Reading

Analyst Recommendations for Codexis (NASDAQ:CDXS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Codexis Right Now?

Before you consider Codexis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.

While Codexis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines